To Compare Safety and Efficacy of Doripenem Versus Imipenem-Cilastatin in Patients With Ventilator-Associated Pneumonia

Phase 3 Terminated 274 enrolled Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to show that doripenem is as effective as imipenem-cilastatin in the treatment of patients with ventilator-associated pneumonia.

Timeline

Start: 2008-04
Primary completion: 2011-06
Completion: 2011-06

Publications

Kollef MH, Chastre J, Clavel M, Restrepo MI, Michiels B, Kaniga K, Cirillo I, Kimko H, Redman R. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care. 2012 Nov 13;16(6):R218. doi: 10.1186/cc11862.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Doripenem	Small molecule	1 g	Intravenous
Comparator	Imipenem-Cilastatin	Unknown	1 g	Intravenous

Indications

No indication recorded.